Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.17
0.00 (0.00%)
At close: Dec 24, 2024, 1:00 PM
13.02
-0.15 (-1.14%)
Pre-market: Dec 26, 2024, 7:19 AM EST
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
$643,904
Profits / Employee
$41,075
Market Cap
41.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| CVS Health | 300,000 |
| IQVIA Holdings | 87,000 |
| GE HealthCare Technologies | 51,000 |
| Cencora | 46,000 |
| Haleon | 25,408 |
| Alcon | 25,315 |
| Edwards Lifesciences | 19,800 |
| Agilent Technologies | 18,100 |
TAK News
- 13 days ago - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas - Business Wire
- 19 days ago - Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors - Seeking Alpha
- 22 days ago - Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Benzinga
- 23 days ago - Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Business Wire
- 5 weeks ago - Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Business Wire
- 7 weeks ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments - Reuters
- 2 months ago - Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - Business Wire